Prelude Therapeutics(PRLD) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms (MPNs). The mutation impacts approximately 95% of patients with polycythemia vera (PV), 60% of patients with essential throm ...